{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T02:56:11Z","timestamp":1769828171446,"version":"3.49.0"},"reference-count":35,"publisher":"Elsevier BV","issue":"17","license":[{"start":{"date-parts":[[2011,11,1]],"date-time":"2011-11-01T00:00:00Z","timestamp":1320105600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2011,11]]},"DOI":"10.1016\/j.ejca.2011.07.014","type":"journal-article","created":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T22:02:29Z","timestamp":1314914549000},"page":"2592-2602","source":"Crossref","is-referenced-by-count":109,"title":["Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: A phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma"],"prefix":"10.1016","volume":"47","clinical-trial-number":[{"clinical-trial-number":"nct00569946","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Yoshihiko","family":"Tomita","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotsugu","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroyuki","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiro-omi","family":"Kanayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuo","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hayakazu","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiji","family":"Imai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiko","family":"Umeyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiichiro","family":"Ozono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Naito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Akaza","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2011.07.014_b0005","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ctrv.2007.12.001","article-title":"Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review","volume":"34","author":"Gupta","year":"2008","journal-title":"Cancer Treat Rev"},{"issue":"Suppl. 4","key":"10.1016\/j.ejca.2011.07.014_b0010","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/annonc\/mdp137","article-title":"Renal cell carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up","volume":"20","author":"Escudier","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2011.07.014_b0015","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1007\/s00345-004-0466-0","article-title":"Novel approaches in the therapy of metastatic renal cell carcinoma","volume":"23","author":"Lam","year":"2005","journal-title":"World J Urol"},{"issue":"Suppl. 10","key":"10.1016\/j.ejca.2011.07.014_b0020","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/annonc\/mdm411","article-title":"Treatment options in renal cell carcinoma: past, present and future","volume":"18","author":"Oudard","year":"2007","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2011.07.014_b0025","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.eururo.2008.12.026","article-title":"Prognosis of Japanese metastatic renal cell carcinoma patients in the cytokine era: a cooperative group report of 1463 patients","volume":"57","author":"Naito","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.ejca.2011.07.014_b0030","unstructured":"Ferlay J, Shin HR, Bray F, et al. GLOBOCAN 2008, cancer incidence and mortality worldwide: IARC Cancer Base No. 10. International Agency for Research on Cancer; 2010. Available from: http:\/\/globocan.iarc.fr."},{"key":"10.1016\/j.ejca.2011.07.014_b0035","doi-asserted-by":"crossref","first-page":"112","DOI":"10.3322\/canjclin.57.2.112","article-title":"Recent progress in the management of advanced renal cell carcinoma","volume":"57","author":"Garcia","year":"2007","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2011.07.014_b0040","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1634\/theoncologist.12-12-1404","article-title":"Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies","volume":"12","author":"Costa","year":"2007","journal-title":"Oncologist"},{"key":"10.1016\/j.ejca.2011.07.014_b0045","doi-asserted-by":"crossref","first-page":"676","DOI":"10.2174\/156800908786733450","article-title":"Anti-angiogenic targets in the treatment of advanced renal cell carcinoma","volume":"8","author":"Heng","year":"2008","journal-title":"Curr Cancer Drug Targets"},{"key":"10.1016\/j.ejca.2011.07.014_b0050","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1586\/14737140.8.1.63","article-title":"VHL inactivation in renal cell carcinoma: implications for diagnosis, prognosis and treatment","volume":"8","author":"Rathmell","year":"2008","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ejca.2011.07.014_b0055","doi-asserted-by":"crossref","first-page":"7272","DOI":"10.1158\/1078-0432.CCR-08-0652","article-title":"Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3","volume":"14","author":"Hu-Lowe","year":"2008","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2011.07.014_b0060","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(07)70285-1","article-title":"Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study","volume":"8","author":"Rixe","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2011.07.014_b0065","doi-asserted-by":"crossref","first-page":"4708","DOI":"10.1200\/JCO.2007.15.9566","article-title":"Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study","volume":"26","author":"Cohen","year":"2008","journal-title":"J Clin Oncol"},{"issue":"Suppl. 15","key":"10.1016\/j.ejca.2011.07.014_b0180","doi-asserted-by":"crossref","first-page":"9006","DOI":"10.1200\/jco.2008.26.15_suppl.9006","article-title":"Axitinib (AG-013736) in patients with metastatic melanoma: a phase II study","volume":"26","author":"Fruehauf","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.07.014_b0075","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1200\/JCO.2008.21.7034","article-title":"Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma","volume":"27","author":"Rini","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.07.014_b0080","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1200\/JCO.2008.20.8355","article-title":"Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study","volume":"27","author":"Schiller","year":"2009","journal-title":"J Clin Oncol"},{"issue":"Suppl. 18","key":"10.1016\/j.ejca.2011.07.014_b0185","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1200\/jco.2007.25.18_suppl.1003","article-title":"A randomized, double-blind phase II study of the oral tyrosine kinase inhibitor (TKI) axitinib (AG-013736) in combination with docetaxel (DOC) compared to DOC plus placebo (PL) in metastatic breast cancer (MBC)","volume":"25","author":"Rugo","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.07.014_b0090","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2011.07.014_b0095","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/S1053-4296(03)00031-6","article-title":"CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment","volume":"13","author":"Trotti","year":"2003","journal-title":"Semin Radiat Oncol"},{"key":"10.1016\/j.ejca.2011.07.014_b0100","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/S0140-6736(08)60661-3","article-title":"Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study","volume":"371","author":"Spano","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2011.07.014_b0105","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2011.07.014_b0110","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2008.19.5511","article-title":"Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial","volume":"27","author":"Escudier","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.07.014_b0115","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal-cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2011.07.014_b0120","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1093\/jjco\/hyp146","article-title":"A phase II study of sunitinib in Japanese patients with metastatic renal cell carcinoma: insights into the treatment, efficacy and safety","volume":"40","author":"Uemura","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.07.014_b0125","doi-asserted-by":"crossref","first-page":"67","DOI":"10.4143\/crt.2009.41.2.67","article-title":"Treatment outcomes of sunitinib treatment in advanced renal cell carcinoma patients: a single cancer center experience in Korea","volume":"41","author":"Hong","year":"2009","journal-title":"Cancer Res Treat"},{"key":"10.1016\/j.ejca.2011.07.014_b0130","doi-asserted-by":"crossref","first-page":"450","DOI":"10.4111\/kju.2010.51.7.450","article-title":"Efficacy and safety of sunitinib on metastatic renal cell carcinoma: a single-institution experience","volume":"51","author":"Hwang","year":"2010","journal-title":"Korean J Urol"},{"key":"10.1016\/j.ejca.2011.07.014_b0135","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1093\/jjco\/hyq073","article-title":"The efficacy and safety of sunitinib in Korean patients with advanced renal cell carcinoma: high incidence of toxicity leads to frequent dose reduction","volume":"40","author":"Yoo","year":"2010","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.ejca.2011.07.014_b0190","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1186\/1471-2407-9-249","article-title":"Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study","volume":"9","author":"Zhang","year":"2009","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ejca.2011.07.014_b0145","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.ejca.2009.11.001","article-title":"VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management","volume":"46","author":"Izzedine","year":"2010","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2011.07.014_b0150","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1093\/jnci\/djk008","article-title":"Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib","volume":"99","author":"Rini","year":"2007","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2011.07.014_b0155","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/annonc\/mdm483","article-title":"Thyroid function test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib","volume":"19","author":"Tamaskar","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2011.07.014_b0195","doi-asserted-by":"crossref","unstructured":"Fujiwara Y, Kiyota N, Chayahara N, et al. Management of axitinib (AG-013736)-induced fatigue and thyroid dysfunction, and predictive biomarkers of axitinib exposure: results from phase I studies in Japanese patients. Invest New Drugs; 2011. doi:10.1007\/s10637-011-9637-1.","DOI":"10.1007\/s10637-011-9637-1"},{"key":"10.1016\/j.ejca.2011.07.014_b0165","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1038\/sj.bjc.6604497","article-title":"The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation","volume":"99","author":"Wolter","year":"2008","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ejca.2011.07.014_b0170","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.urolonc.2009.08.011","article-title":"Abnormalities of thyroid function in Japanese patients with metastatic renal cell carcinoma treated with sorafenib: a prospective evaluation","volume":"28","author":"Miyake","year":"2009","journal-title":"Urol Oncol"},{"key":"10.1016\/j.ejca.2011.07.014_b0175","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nrclinonc.2009.63","article-title":"Biomarkers of response and resistance to antiangiogenic therapy","volume":"6","author":"Jain","year":"2009","journal-title":"Nat Rev Clin Oncol"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804911005508?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804911005508?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,23]],"date-time":"2020-06-23T02:51:12Z","timestamp":1592880672000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804911005508"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11]]},"references-count":35,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2011,11]]}},"alternative-id":["S0959804911005508"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2011.07.014","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2011,11]]}}}